Switch to:
Also traded in: Germany, Japan

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.77
OTCPK:TKPYY's Cash to Debt is ranked lower than
66% of the 778 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.15 vs. OTCPK:TKPYY: 0.77 )
Ranked among companies with meaningful Cash to Debt only.
OTCPK:TKPYY' s Cash to Debt Range Over the Past 10 Years
Min: 0.7  Med: 38.39 Max: N/A
Current: 0.77
Equity to Asset 0.47
OTCPK:TKPYY's Equity to Asset is ranked lower than
72% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. OTCPK:TKPYY: 0.47 )
Ranked among companies with meaningful Equity to Asset only.
OTCPK:TKPYY' s Equity to Asset Range Over the Past 10 Years
Min: 0.47  Med: 0.55 Max: 0.76
Current: 0.47
0.47
0.76
Interest Coverage 7.84
OTCPK:TKPYY's Interest Coverage is ranked lower than
76% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.32 vs. OTCPK:TKPYY: 7.84 )
Ranked among companies with meaningful Interest Coverage only.
OTCPK:TKPYY' s Interest Coverage Range Over the Past 10 Years
Min: 3.18  Med: 189.06 Max: 1856.28
Current: 7.84
3.18
1856.28
F-Score: 6
Z-Score: 2.58
M-Score: -2.49
WACC vs ROIC
5.04%
7.54%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 13.05
OTCPK:TKPYY's Operating margin (%) is ranked higher than
65% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.44 vs. OTCPK:TKPYY: 13.05 )
Ranked among companies with meaningful Operating margin (%) only.
OTCPK:TKPYY' s Operating margin (%) Range Over the Past 10 Years
Min: -7.27  Med: 18.74 Max: 35.13
Current: 13.05
-7.27
35.13
Net-margin (%) 8.64
OTCPK:TKPYY's Net-margin (%) is ranked higher than
61% of the 726 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. OTCPK:TKPYY: 8.64 )
Ranked among companies with meaningful Net-margin (%) only.
OTCPK:TKPYY' s Net-margin (%) Range Over the Past 10 Years
Min: -8.2  Med: 12.39 Max: 25.85
Current: 8.64
-8.2
25.85
ROE (%) 7.65
OTCPK:TKPYY's ROE (%) is ranked higher than
54% of the 753 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.76 vs. OTCPK:TKPYY: 7.65 )
Ranked among companies with meaningful ROE (%) only.
OTCPK:TKPYY' s ROE (%) Range Over the Past 10 Years
Min: -6.33  Med: 8.85 Max: 15.12
Current: 7.65
-6.33
15.12
ROA (%) 3.81
OTCPK:TKPYY's ROA (%) is ranked higher than
52% of the 783 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. OTCPK:TKPYY: 3.81 )
Ranked among companies with meaningful ROA (%) only.
OTCPK:TKPYY' s ROA (%) Range Over the Past 10 Years
Min: -3.29  Med: 6.12 Max: 12
Current: 3.81
-3.29
12
ROC (Joel Greenblatt) (%) 42.75
OTCPK:TKPYY's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.07 vs. OTCPK:TKPYY: 42.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OTCPK:TKPYY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -19.36  Med: 48.9 Max: 207.72
Current: 42.75
-19.36
207.72
Revenue Growth (3Y)(%) 5.20
OTCPK:TKPYY's Revenue Growth (3Y)(%) is ranked lower than
51% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. OTCPK:TKPYY: 5.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OTCPK:TKPYY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0.2  Med: 5.05 Max: 11.6
Current: 5.2
0.2
11.6
EBITDA Growth (3Y)(%) -4.40
OTCPK:TKPYY's EBITDA Growth (3Y)(%) is ranked lower than
73% of the 564 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.30 vs. OTCPK:TKPYY: -4.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OTCPK:TKPYY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -28.3  Med: -1.15 Max: 24.8
Current: -4.4
-28.3
24.8
EPS Growth (3Y)(%) -18.50
OTCPK:TKPYY's EPS Growth (3Y)(%) is ranked lower than
80% of the 529 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. OTCPK:TKPYY: -18.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OTCPK:TKPYY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -24.5  Med: -0.8 Max: 31.4
Current: -18.5
-24.5
31.4
» OTCPK:TKPYY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with TKPYY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NYSE:ZTS, OTCPK:TEVJF, NAS:MYL, OTCPK:ESALY, OTCPK:SGIOY, OTCPK:MKGAY, NYSE:PRGO, OTCPK:MTZPY, NYSE:VRX, NYSE:MNK, NYSE:RDY, OTCPK:MDABY, OTCPK:HKMPF, OTCPK:SFOSF, OTCPK:HLUYY, NAS:OPK, OTCPK:HYPMY, OTCPK:IPSEY, NAS:ENDP, NYSE:TARO » details
Traded in other countries:TKD.Germany, 4502.Japan,
Takeda Pharmaceutical Co Ltd is engaged in the manufacturing, marketing and import and export of pharmaceutical drugs.

Takeda Pharmaceutical Co Ltd was founded on June 12, 1781 and was incorporated on January 29, 1925. The Company is primarily engaged in the any manufacture and sale of pharmaceuticals, food supplements, and chemical products such as polyurethane. The Company also produces food, agrochemicals, and environment-related products such as pollution detectors. It is also engaged in the research, development, and promotion of its products through its related companies in the US, Europe, and Asia.

Ratios

vs
industry
vs
history
P/E(ttm) 24.98
TKPYY's P/E(ttm) is ranked higher than
59% of the 538 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.52 vs. TKPYY: 24.98 )
Ranked among companies with meaningful P/E(ttm) only.
TKPYY' s P/E(ttm) Range Over the Past 10 Years
Min: 6.52  Med: 19.37 Max: 90.66
Current: 24.98
6.52
90.66
Forward P/E 27.55
TKPYY's Forward P/E is ranked lower than
72% of the 69 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.76 vs. TKPYY: 27.55 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 24.98
TKPYY's PE(NRI) is ranked higher than
59% of the 537 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.50 vs. TKPYY: 24.98 )
Ranked among companies with meaningful PE(NRI) only.
TKPYY' s PE(NRI) Range Over the Past 10 Years
Min: 6.52  Med: 19.37 Max: 90.66
Current: 24.98
6.52
90.66
Price/Owner Earnings (ttm) 37.93
TKPYY's Price/Owner Earnings (ttm) is ranked lower than
53% of the 276 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.08 vs. TKPYY: 37.93 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
TKPYY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 11.64  Med: 45.13 Max: 581.3
Current: 37.93
11.64
581.3
P/B 2.14
TKPYY's P/B is ranked higher than
65% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.08 vs. TKPYY: 2.14 )
Ranked among companies with meaningful P/B only.
TKPYY' s P/B Range Over the Past 10 Years
Min: 1.22  Med: 1.54 Max: 2.44
Current: 2.14
1.22
2.44
P/S 2.16
TKPYY's P/S is ranked higher than
61% of the 695 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. TKPYY: 2.16 )
Ranked among companies with meaningful P/S only.
TKPYY' s P/S Range Over the Past 10 Years
Min: 1.67  Med: 2.2 Max: 12.29
Current: 2.16
1.67
12.29
PFCF 43.64
TKPYY's PFCF is ranked lower than
69% of the 193 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.56 vs. TKPYY: 43.64 )
Ranked among companies with meaningful PFCF only.
TKPYY' s PFCF Range Over the Past 10 Years
Min: 10.03  Med: 42.21 Max: 204.92
Current: 43.64
10.03
204.92
POCF 30.55
TKPYY's POCF is ranked lower than
71% of the 256 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.62 vs. TKPYY: 30.55 )
Ranked among companies with meaningful POCF only.
TKPYY' s POCF Range Over the Past 10 Years
Min: 7.75  Med: 29.82 Max: 69.13
Current: 30.55
7.75
69.13
EV-to-EBIT 16.24
TKPYY's EV-to-EBIT is ranked higher than
65% of the 529 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.31 vs. TKPYY: 16.24 )
Ranked among companies with meaningful EV-to-EBIT only.
TKPYY' s EV-to-EBIT Range Over the Past 10 Years
Min: -47.1  Med: 11.1 Max: 46.2
Current: 16.24
-47.1
46.2
EV-to-EBITDA 10.95
TKPYY's EV-to-EBITDA is ranked higher than
73% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.21 vs. TKPYY: 10.95 )
Ranked among companies with meaningful EV-to-EBITDA only.
TKPYY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.3  Med: 11.2 Max: 2171.3
Current: 10.95
3.3
2171.3
Shiller P/E 10.38
TKPYY's Shiller P/E is ranked higher than
94% of the 159 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.59 vs. TKPYY: 10.38 )
Ranked among companies with meaningful Shiller P/E only.
TKPYY' s Shiller P/E Range Over the Past 10 Years
Min: 8.74  Med: 9.63 Max: 10.44
Current: 10.38
8.74
10.44
Current Ratio 1.79
TKPYY's Current Ratio is ranked lower than
64% of the 678 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.47 vs. TKPYY: 1.79 )
Ranked among companies with meaningful Current Ratio only.
TKPYY' s Current Ratio Range Over the Past 10 Years
Min: 1.21  Med: 2.21 Max: 4
Current: 1.79
1.21
4
Quick Ratio 1.50
TKPYY's Quick Ratio is ranked lower than
59% of the 678 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. TKPYY: 1.50 )
Ranked among companies with meaningful Quick Ratio only.
TKPYY' s Quick Ratio Range Over the Past 10 Years
Min: 1  Med: 1.84 Max: 3.64
Current: 1.5
1
3.64
Days Inventory 174.98
TKPYY's Days Inventory is ranked lower than
75% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.00 vs. TKPYY: 174.98 )
Ranked among companies with meaningful Days Inventory only.
TKPYY' s Days Inventory Range Over the Past 10 Years
Min: 132.84  Med: 162.63 Max: 180.99
Current: 174.98
132.84
180.99

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.29
TKPYY's Dividend Yield is ranked higher than
87% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.52 vs. TKPYY: 3.29 )
Ranked among companies with meaningful Dividend Yield only.
TKPYY' s Dividend Yield Range Over the Past 10 Years
Min: 2.71  Med: 4.49 Max: 6.48
Current: 3.29
2.71
6.48
Dividend Payout 0.94
TKPYY's Dividend Payout is ranked lower than
86% of the 372 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.35 vs. TKPYY: 0.94 )
Ranked among companies with meaningful Dividend Payout only.
TKPYY' s Dividend Payout Range Over the Past 10 Years
Min: 0.16  Med: 0.92 Max: 7.35
Current: 0.94
0.16
7.35
Forward Dividend Yield 3.57
TKPYY's Forward Dividend Yield is ranked higher than
87% of the 579 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.51 vs. TKPYY: 3.57 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.29
TKPYY's Yield on cost (5-Year) is ranked higher than
76% of the 717 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.04 vs. TKPYY: 3.29 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TKPYY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.71  Med: 4.49 Max: 6.48
Current: 3.29
2.71
6.48
3-Year Average Share Buyback Ratio 0.30
TKPYY's 3-Year Average Share Buyback Ratio is ranked higher than
86% of the 432 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. TKPYY: 0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TKPYY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.3  Med: 0 Max: 3.9
Current: 0.3
-0.3
3.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 8.76
TKPYY's Price/Tangible Book is ranked lower than
79% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. TKPYY: 8.76 )
Ranked among companies with meaningful Price/Tangible Book only.
TKPYY' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.85  Med: 6.96 Max: 13.07
Current: 8.76
1.85
13.07
Price/Projected FCF 1.98
TKPYY's Price/Projected FCF is ranked higher than
61% of the 287 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.65 vs. TKPYY: 1.98 )
Ranked among companies with meaningful Price/Projected FCF only.
TKPYY' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.14  Med: 1.42 Max: 2.13
Current: 1.98
1.14
2.13
Price/Median PS Value 0.98
TKPYY's Price/Median PS Value is ranked higher than
71% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. TKPYY: 0.98 )
Ranked among companies with meaningful Price/Median PS Value only.
TKPYY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.81  Med: 1.01 Max: 5.17
Current: 0.98
0.81
5.17
Price/Graham Number 3.12
TKPYY's Price/Graham Number is ranked lower than
61% of the 400 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. TKPYY: 3.12 )
Ranked among companies with meaningful Price/Graham Number only.
TKPYY' s Price/Graham Number Range Over the Past 10 Years
Min: 0.67  Med: 2.51 Max: 4.79
Current: 3.12
0.67
4.79
Earnings Yield (Greenblatt) (%) 6.17
TKPYY's Earnings Yield (Greenblatt) (%) is ranked higher than
76% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. TKPYY: 6.17 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TKPYY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.2  Med: 7.3 Max: 23.8
Current: 6.17
2.2
23.8
Forward Rate of Return (Yacktman) (%) -35.09
TKPYY's Forward Rate of Return (Yacktman) (%) is ranked lower than
96% of the 330 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.64 vs. TKPYY: -35.09 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TKPYY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -46.9  Med: -16.3 Max: 15.8
Current: -35.09
-46.9
15.8

More Statistics

Revenue (TTM) (Mil) $15,618
EPS (TTM) $ 0.88
Beta0.37
Short Percentage of Float0.00%
52-Week Range $20.32 - 25.72
Shares Outstanding (Mil)1,567.23

Analyst Estimate

Mar17 Mar18
Revenue (Mil $) 16,853 17,999
EPS ($) 0.87 1.14
EPS w/o NRI ($) 0.87 1.14
EPS Growth Rate
(3Y to 5Y Estimate)
3.14%
Dividends Per Share ($) 0.89 0.89
» More Articles for OTCPK:TKPYY

Headlines

Articles On GuruFocus.com
Seth Klarman Buys Pharmaceutical Company's Shares to Fund Drug Launch Oct 12 2015 
5 Popular Asian Stocks Held By the Gurus Apr 16 2015 
Don't Quit on Teva Just Yet Feb 20 2014 
Soros´ Bet on Teva’s Transition (A Transition for Better or for Worse?) Dec 18 2013 
T. Rowe Price Japan Fund Top 5 New Buys Oct 17 2013 

More From Other Websites
3:17 pm Takeda Pharma announces additional interim data on the long-term use of vedolizumab in... Sep 28 2016
Additional Interim Data Supporting Long-Term Use of Vedolizumab in Patients with Ulcerative Colitis... Sep 28 2016
Amgen's multiple myeloma drug falls short in late stage study Sep 27 2016
Takeda's Biotech M&A Menu Is Long, Complex Sep 21 2016
Takeda and Affilogic enter into Research Collaboration to Develop Nanofitin®-based Therapies in... Sep 21 2016
Takeda and Zydus Cadila partner to address the global threat of Chikungunya Sep 20 2016
Favorable Benefit: Risk Profile for Vedolizumab as Induction and Maintenance Therapy in TNF-Naïve... Sep 16 2016
Takeda Receives Positive CHMP Opinion for Conditional Approval of NINLAROTM (ixazomib), the First... Sep 16 2016
Bluebird Bio (BLUE) Stock Jumping, Goldman Adds to Conviction Buy List Sep 15 2016
Here's a Reason Why Bluebird Bio (BLUE) Stock Is Jumping Today Sep 14 2016
Here's a Reason Why Synergy Pharma (SGYP) Stock Is Rallying Today Sep 14 2016
Will Takeda Pharmaceutical (TKPYY) Stock Be Helped By Pursuit of $15 Billion in U.S. Deals? Sep 14 2016
Japan's Takeda prepares $15 billion for U.S. acquisitions - FT Sep 14 2016
[$$] Takeda earmarks $15bn for US pharma acquisitions Sep 13 2016
Takeda and PRA Health Sciences Announce Transformational Clinical Development and Marketed Product... Sep 12 2016
Takeda Supports Global Expansion of the American Cancer Society’s Relay For Life (RFL) Sep 12 2016
Takeda Launches Wearable Digital Technology Pilot Program to Support Patients and Healthcare... Sep 07 2016
Takeda Initiates Global Phase 3 Clinical Trial (TIDES) of Dengue Vaccine Candidate (TAK-003) Sep 07 2016
6 Drug Stocks in Focus as Zika Virus Fear Spreads Sep 06 2016
[$$] Takeda Gets Financial Help From U.S. in Developing Zika Vaccine Sep 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)